PTC Therapeutics, Inc. Files For Initial Public Offering

SOUTH PLAINFIELD, N.J., March 31 /PRNewswire/ -- PTC Therapeutics, Inc. today announced that the company has filed with the Securities and Exchange Commission a registration statement relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be sold by PTC Therapeutics, Inc.

(Logo: )

Morgan Stanley & Co. Incorporated will act as sole book-runner and lead manager, J.P. Morgan Securities Inc. will act as co-lead manager and Pacific Growth Equities, LLC will act as co-manager in the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. When available, a preliminary prospectus may be obtained from Morgan Stanley & Co. Incorporated, by emailing, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, New York 10036, by telephone at 212-761-6775.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC has assembled proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities. PTC's current pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology, and infectious diseases.

Photo: Therapeutics, Inc.

CONTACT: Jane Baj of PTC Therapeutics, Inc., +1-908-222-7000, ext. 167,

Back to news